Novartis AG

Novartis AG (NVS) News & Events

$146.880

+4.612 (+3.14%)At close

NVS News

NVS Events

10/7 12:00

Novartis' Rhapsido Approved by FDA for Adult Dermographism

Novartis announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. Rhapsido is now the only treatment indicated for the two most common forms of chronic hives: chronic spontaneous urticaria and symptomatic dermographism, the company said in a statement.

10/7 07:30

Novartis to Present 46 MS Research Data at MSToronto2026

Novartis will present new data from its multiple sclerosis, MS, portfolio with 46 abstracts at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. Among these is a late-breaking abstract featuring the Phase III REMODEL-1/-2 results, underscoring the potential of remibrutinib and reinforcing the company's long-standing commitment to advancing care for people living with MS. A second late-breaking abstract will present new Kesimpta data in pediatric MS. Additional presentations will further expand the Kesimpta evidence base, including research on pregnancy outcomes and breastfeeding that aims to inform family planning decisions, as well as the use of Kesimpta versus disease-modifying therapies commonly used as first-line treatments in treatment-naive patients.

10/2 06:30

Abogen Biosciences Enters $575M Agreement with Novartis

Abogen Biosciences, a clinical-stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis to advance RNA-encoded therapeutics. The agreement includes an exclusive worldwide license to Abogen's lead asset, ABO2203, as well as options to exclusively license other potential programs leveraging Abogen's proprietary RNA platform. Under the agreement, Novartis will also have the exclusive option to license a number of next-generation therapeutic assets developed on Abogen's RNA platform. Under the terms of the proposed agreement, Abogen will receive an upfront payment of $575M and, if all options on all programs are exercised, Abogen is eligible to receive up to approximately $7.2B in potential milestone payments, subject to the achievement of agreed development, regulatory and commercial milestones. In addition, Abogen may be eligible to receive potential royalties on future product sales. The transaction is subject to customary closing conditions, including required regulatory clearances. "Achieving effective and durable immune reset remains an important goal across a number of autoimmune diseases," said Fiona Marshall, President of Biomedical Research at Novartis. "mRNA-encoded T-cell engagers represent an innovative approach that could complement existing therapeutic modalities by enabling in vivo production of these molecules. We look forward to further developing the potential of ABO2203 and additional possible applications of Abogen's RNA platform."

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading